Cytokine Filtration in Lung Transplantation: A Swedish National Study (GLUSorb)

Launched by LUND UNIVERSITY HOSPITAL · Aug 31, 2022

Keywords

ClinConnect Summary

The GLUSorb trial is a study looking at a new approach to help improve outcomes for people who have received a lung transplant. Lung transplants are crucial for patients with severe lung diseases, but many face complications shortly after the surgery, which can affect their survival. This study aims to see if a treatment that filters out certain substances called cytokines can help prevent early complications after the transplant, known as primary graft dysfunction (PGD). By comparing patients who receive this treatment with those who do not, researchers hope to find better ways to support lung transplant recipients and improve their chances of a longer, healthier life.

To be eligible for this study, participants should be between 18 and 75 years old and must be scheduled to undergo double lung transplantation at one of the trial sites. However, those who have had an organ transplant before or who have certain medical conditions requiring specific immunosuppressive medications cannot participate. If you join the study, you will receive either the cytokine filtration treatment or standard care, and your progress will be closely monitored. This trial is currently recruiting participants and represents an important step toward improving lung transplant outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • • Eligibility to undergo double lung transplantation at either trial site
• Exclusion Criteria:
• • 1. Age \<18 years
• • 2. Previous organ transplantation
• 3. Presence of any conditions at the time of surgery that require immunosuppressive therapy. Immunosuppressive therapy is defined as:
• • 1. Cyclosporine, Tacrolimus, Everolimus, or Sirolimus, minimum 1 month of treatment prior to transplantation and active treatment at the time of transplantation.
• • 2. Any form of antibody-based treatment that is known for having an immunomodulatory effect taken up to 1 week before transplantation.
• • 4. Non-consent